Provided by Tiger Trade Technology Pte. Ltd.

Rani Therapeutics Holdings

0.8800
+0.02903.41%
Post-market: 0.8670-0.0130-1.48%19:38 EDT
Volume:708.40K
Turnover:622.71K
Market Cap:122.67M
PE:-4.05
High:0.8974
Open:0.8787
Low:0.8600
Close:0.8510
52wk High:3.87
52wk Low:0.4404
Shares:139.40M
Float Shares:85.67M
Volume Ratio:0.58
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2174
EPS(LYR):-0.4500
ROE:-172.15%
ROA:-52.99%
PB:3.13
PE(LYR):-1.96

Loading ...

Rani Therapeutics Announces Positive Initial Phase 1a Data for Rt-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

THOMSON REUTERS
·
Jul 15

Rani Therapeutics - Phase 1a Study Expanded with Additional Cohort to Define Pharmacokinetic Relationship

THOMSON REUTERS
·
Jul 15

Rani Therapeutics - no Adverse Events Attributed to Ranipill Capsule; Treatment-related Events were Mild

THOMSON REUTERS
·
Jul 15

Rani Therapeutics - Phase 1B Study Expected to Begin in 2026 with Data Anticipated in 2027

THOMSON REUTERS
·
Jul 15

Rani Therapeutics Announces R&D Collaboration with Pegbio

Reuters
·
Jul 10

Rani Therapeutics announces research, development collaboration with PegBio

TIPRANKS
·
Jul 10

Rani Therapeutics Partners with Pegbio to Develop Oral Obesity Drug Candidates

Reuters
·
Jul 10

Rani Therapeutics Announces Research and Development Collaboration with Pegbio to Expand Obesity Pipeline Across Multiple Novel Candidates

THOMSON REUTERS
·
Jul 10

Rani Therapeutics Holdings - Co and Pegbio to Develop Ranipill Formulations for Multiple Obesity Candidates

THOMSON REUTERS
·
Jul 10

Rani Therapeutics Files Form 3 for CFO Nicholas Maestas on Initial Beneficial Ownership Statement

Reuters
·
Jul 09

Rani Therapeutics Names Nicholas Maestas CFO, Replacing Svai Sanford

Reuters
·
Jun 29

Rani Therapeutics Holdings - Nicholas Maestas Succeeds Svai Sanford as Chief Financial Officer

THOMSON REUTERS
·
Jun 29

Rani Therapeutics stockholders elect directors at annual meeting

Reuters
·
May 29

Rani Therapeutics Announces $20 Million Equity Financing

TIPRANKS
·
May 27

Rani Therapeutics prices USD 20 million registered direct stock offering at USD 1.07 per share

Reuters
·
May 26

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class a Common Stock Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
May 26

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
May 26

Lake Street Sticks to Their Buy Rating for Rani Therapeutics Holdings (RANI)

TIPRANKS
·
May 19

Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price

TIPRANKS
·
May 17

Rani Therapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16